TTI 621

Drug Profile

TTI 621

Alternative Names: CD47 antigen/SIRPalpha protein modulator - Trillium Therapeutics; SIRPaFc; SIRPalphaFc; TTI-621

Latest Information Update: 20 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Hospital for Sick Children; University Health Network
  • Developer Trillium Therapeutics Inc
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; SIRPA protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Mycosis fungoides; Sezary syndrome; Small cell lung cancer; Solid tumours

Most Recent Events

  • 20 Mar 2018 TTI 621 receives Orphan drug status for Cutaneous T-cell lymphoma in USA
  • 11 Dec 2017 Efficacy and adverse events data from phase I trials in Haematological malignancies and Mycosis fungoides released by Trillium
  • 09 Dec 2017 Efficacy and adverse events data from a phase I trial in Solid tumours and Mycosis fungoides presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top